Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.01 per share, beating the Zacks Consensus Estimate of $1.28 per share. This compares to earnings of $2.33 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 57.03%. A quarter ago, it was expected that this maker of instruments used in biomedical research would post earnings of $2.12 per share when it actually produced earnings of $3.11, delivering a surprise of 46. ...

Exhibit 99.1 Press Release Bio-Rad Reports Third-Quarter 2024 Financial Results HERCULES, Calif.—October 30, 2024 -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2024. Third-quarter 2024 total net sales were $649.7 million, an increase of 2.8 percent compared to $632.1 million reported for the third quarter of 2023. On a currency-neutral basis, quarterl ...

Financial Performance - Bio-Techne Corporation reported first quarter fiscal 2025 net sales of $289.5 million, representing a 5% increase compared to the same quarter last year, with organic revenue growth of 4% [2][7] - GAAP earnings per share (EPS) decreased to $0.21 from $0.31 in the prior year, while adjusted EPS increased to $0.42 from $0.41 [2][8] - GAAP operating income fell 28% to $40.0 million, resulting in a GAAP operating margin of 13.8%, down from 20.2% in the same quarter last year [7][8] Segment Performance - The Protein Sciences segment reported net sales of $204.5 million, remaining flat compared to $204.7 million in the same quarter last year, with an organic growth of 1% [9] - The Diagnostics and Spatial Biology segment achieved net sales of $83.2 million, a 14% increase from $72.8 million in the prior year, with organic revenue growth also at 14% [10] Management Commentary - The CEO highlighted strong execution in the Diagnostics & Spatial Biology segment and robust growth in the cell and gene therapy business, particularly in GMP reagent offerings [5] - The company expressed confidence in the recovery of the biotech end market, supported by favorable funding dynamics [5] Cash Flow and Financial Position - Cash and cash equivalents at the end of the quarter were $187.5 million, up from $151.8 million at the beginning of the period [31] - The company reported net cash provided by operating activities of $63.9 million, compared to $59.4 million in the same quarter last year [31]

With the third-quarter earnings season in full swing, it's going to be a pivotal week for numerous firms within the medical device sector. The latest Earnings Preview report indicates strong earnings and revenue growth within the Medical sector. The projected top and bottom-line improvements can be attributed to sustained demand for medical products and services, and favorable pricing strategies, which are likely to offset the shortcomings generated from worldwide geopolitical issues, high-interest expense ...

Core Viewpoint - Tonix Pharmaceuticals Holding Corp. is actively participating in the upcoming BIO-Europe® conference, highlighting its focus on biopharmaceutical development and its pipeline of products aimed at addressing various health challenges [1][3]. Company Overview - Tonix Pharmaceuticals is a fully integrated biopharmaceutical company with marketed products and a robust pipeline [3]. - The company specializes in therapies for pain management and public health challenges, particularly focusing on central nervous system (CNS) disorders [3]. - Tonix's commercial subsidiary, Tonix Medicines, markets Zembrace® SymTouch® and Tosymra® for acute migraine treatment [3]. Product Development - The company is advancing TNX-102 SL, a candidate for fibromyalgia management, for which an NDA has been submitted based on two significant Phase 3 studies [3]. - TNX-102 SL has received Fast Track designation from the FDA for fibromyalgia treatment and is also being developed for acute stress reaction and disorder [3]. - Other notable products in development include TNX-1300 for cocaine intoxication, which has FDA Breakthrough Therapy designation, and TNX-1500 for organ transplant rejection and autoimmune diseases [3]. - Tonix is also developing TNX-2900 for Prader-Willi syndrome and a vaccine for mpox, TNX-801 [3]. - The company has secured a contract with the U.S. Department of Defense for up to $34 million over five years to develop TNX-4200, targeting broad-spectrum antiviral agents [3]. Conference Participation - Seth Lederman, M.D., CEO of Tonix Pharmaceuticals, will present at the BIO-Europe® conference on November 4, 2024, at 1:00 p.m. CET [1].

Core Insights - BIO-key International, Inc. has received a $910,000 order from a long-term financial services customer to upgrade to its "fingerprint only" Biometric Customer Identification Technology [1][2] - The upgrade will streamline customer verification processes, allowing identification through a simple fingerprint scan, eliminating the need for cards or account numbers, and saving approximately thirty seconds per client encounter [2][3] - Following the full deployment of the enhanced solution in 2025, BIO-key anticipates an increase in annual recurring revenue (ARR) from this customer to approximately $1.4 million [4] Company Technology and Strategy - The new identification solution will be hosted on Amazon Web Services (AWS) to support real-time, one-to-many biometric identification, enhancing the existing verification process [3] - The financial services customer aims to provide a superior client experience and protect against fraud by leveraging advanced biometric technology [5] - BIO-key's technology is designed to secure access for over forty million users, offering various authentication options including phoneless, tokenless, and passwordless solutions [5]

HOUSTON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that members of its senior leadership team will be presenting and be available for one-on-one meetings with investors at the following upcoming investor conferences. 2024 ThinkEqui ...

SEATTLE, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ: ATOS) (“Atossa” or the “Company”), today announced that Steven Quay, M.D., Ph.D., Chairman and Chief Executive Officer, will join Per Hall, M.D., Professor of Epidemiology at the Department of Medical Epidemiology and Biostatistics at Karolinska Institute, at a fireside chat at BIO-Europe 2024. During the fireside chat, Drs. Quay and Hall will discuss a meaningful approach to combining a state-of-the-art, artificial intelligence ( ...

Core Viewpoint - Bio-Rad Laboratories, Inc. is set to release its third-quarter 2024 results on October 30, with expectations of mixed performance due to various market challenges and product demand dynamics [1]. Group 1: Earnings and Revenue Estimates - The Zacks Consensus Estimate for revenues in Q3 2024 is $639.9 million, reflecting a 0.8% increase from the previous year [2]. - The Zacks Consensus Estimate for EPS is $1.28, indicating a significant year-over-year decline of 45.1% [2]. - The earnings estimate has decreased by 40.2% over the past 30 days [3]. Group 2: Factors Affecting Performance - Weakness in the biotech and biopharma markets has negatively impacted sales of Life Science tools and bioprocessing products, with particular challenges in China [4]. - The process chromatography segment is expected to see a sales decline due to ongoing destocking trends in the industry [4]. - In Asia, constrained funding in Japan and soft government spending on life science research are likely to have hindered growth [4]. Group 3: Positive Developments - Despite the challenges, there is demand for the Droplet Digital PCR (ddPCR) platform, particularly in oncology and cell and gene therapy markets [5]. - The launch of new life science platforms, including the ChemiDoc Imaging Systems and a cost-effective single-cell sample prep solution, is expected to positively impact Q3 performance [5]. - The Clinical Diagnostics segment is projected to see a revenue increase of 41.9% year over year to $267.6 million, driven by demand for quality control immunohematology and blood typing products [6]. Group 4: Segment Revenue Projections - The Clinical Diagnostics segment is expected to grow, with revenues projected to increase 57.9% year over year to $369.7 million [7].

Core Insights - BIO-key International, Inc. will sponsor, speak, and exhibit at ISC2 Security Congress 2024, focusing on Passkeys and zero trust concepts in cybersecurity [1][3] - The company emphasizes its unique phoneless, tokenless, and passwordless biometric authentication solutions, which address the needs of enterprise users in phone-free environments [2][5] Company Overview - BIO-key provides innovative identity and access management (IAM) solutions, securing access for over 35 million users with a focus on biometric authentication [6] - The company's PortalGuard® platform helps organizations balance risk, flexibility, and productivity for users and identity administrators [2][6] Event Details - ISC2 Security Congress 2024 is themed "Boldly Forward" and aims to inspire cybersecurity professionals to enhance their skills and strategies [3] - BIO-key will host a session titled "Introducing Passkey:YOU – a Passwordless Authentication Solution that Checks All the Boxes" on October 14, 2024 [4] Product Highlights - The new offering, Passkey:YOU, provides a secure authentication experience without the need for phones or hardware tokens, reducing total cost of ownership [2][5] - The integration of passkeys and biometric authentication is expected to accelerate zero trust strategies for enterprises [5]